Mark Bachleda - Jun 9, 2025 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Charles Newton, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Jun 9, 2025
Transactions value $
$0
Form type
3
Date filed
6/11/2025, 05:42 PM
Previous filing
Mar 20, 2023
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bachleda Mark Director C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO /s/ Charles Newton, as Attorney-in-Fact 2025-06-11 0001887762

No securities are beneficially owned.